Abstract:Background: In recent years, taxanes play an important role in chemotherapy of breast cancer patients, and its response rate is about 50%. Taxanes is primarily metabolized by CYP450 in liver microsome, and it also is a substrate for P-glycoprotein (the coded product of MDR1 gene). The interindividual heterogeneity in drug-metabolizing enzymes and transporters has contributed to the variability on anti-cancer efficacy of taxanes in breast cancer patients. Several studies showed that the pharmacokinetics of taxanes was influenced by the MDR1 polymorphisms. The aim of this study is to investigate the relationship between MDR1 gene polymorphisms and taxanes-based chemotherapy responses, and provides useful information for clinical personalized medicine and prognostic judgment. Material and Methods: Genotyping of MDR1 variants was determined in the blood samples from 142 Chinese Han patients with breast cancer, by PCR-RFLP. The association of the gene polymorphisms of MDR1 C1236T at exon 12, G2677T/A at exon 21 and C3435T at exon 26 with chemotherapy responses was analyzed on the 63 patients, who received taxanes-based neoadjuvant chemotherapy [56 cases with TA (taxanes and anthracycline), 7 cases with TAC (C: cyclophosphamide)] and had the intact treatment follow-up information. Results: In the 142 breast cancer patients, the frequencies of C1236T, G2677T, G2677A and C3435T variant alleles was 70.7%,52.1%,2.5% and 46.5%, respectively, and the frequency of 3435T allele was significantly higher in comparison with that in healthy subjects (34.7%). In the 63 patients with neoadjuvant chemotherapy, the overall clinical response rate (CR+PR) to chemotherapy was 66.7%. 3435TT genotype was showed to be related to taxanes-based chemotherapy, and its efficient rate was 23.1%, significantly lower than that of patients carrying C allele (73.5%; x2 = 9.125, P=0.003). The 3 SNPs were in linkage disequilibrium, and the 4 haplotypes TTT, TGC, CGC and TTC were 90.6 % of all. The patients who carrying 2677G-3435C haplotype showed better response to chemotherapy compared with those with the other haplotypes combined (72.1% vs 40.0%;x 2 =9.125, P=0.003). The response rate of the patients with 2677T-3435T haplotype or 1236T-3435T haplotype (54.3% or 54.9%) were lower than that of the patients harboring the other haplotypes (82.4% or 91.7%;x 2 =4.128 and x 2 =4.118, P =0.042 for both) respectively, and the efficient rate of the patients with 1236T-2677T-3435T (54.3%) were also lower than that of the patients with other haplotypes combined (82.4%;x 2 =4.128, P=0.042). Conclusion: C1236T, G2677T/A and C3435T of MDR1 gene were polymorphic with different frequency in breast cancer patients. The analyses of MDR1 C3435T genotype and its haplotypes with C1236T or G2677T/A are valuable for predicting the taxanes-based chemotherapy responses in breast cancer patients, which deserve the further study. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-21.

A Single-Nucleotide Polymorphism of the Beta 2-Adrenergic Receptor Gene Can Predict Pathological Complete Response to Taxane- and Platinum-Based Neoadjuvant Chemotherapy in Breast Cancer.

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

P5-19-07: the Effects of ABCC2 and SLCO1B3 Single Nucleotide Polymorphisms on Docetaxel-Induced Leukopenia in Breast Cancer Patients.

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

Polymorphisms in Microrna Let-7 Binding Sites of the HIF1AN and CLDN12 Genes Can Predict Pathologic Complete Response to Taxane- and Platinum-Based Neoadjuvant Chemotherapy in Breast Cancer.

The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer.

OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Prognostic and Predictive Markers for Early Stage Triple‐Negative Breast Cancer Treated With Platinum‐Based Neoadjuvant Chemotherapy

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Influence of single nucleotide polymorphisms in ABCB 1 , ABCG 2 and ABCC 2 on clinical outcomes to paclitaxel-platinum chemotherapy in patients with non-small-cell lung cancer

Abstract P2-09-21: Effect of MDR1 Gene Polymorphisms and Haplotypes on Taxanes-Based Chemotherapy Responses in Chinese Han Patients with Breast Cancer

ABCB1 Polymorphism Predicts the Toxicity and Clinical Outcome of Lung Cancer Patients with Taxane‐based Chemotherapy

[Association Between ABCB1 G2677T/A Polymorphisms and Chemosensitivity of Paclitaxel in Advanced Gastric Cancer].

XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.

Polymorphisms in PARP1 Predict Disease-Free Survival of Triple-Negative Breast Cancer Patients Treated with Anthracycline/taxane Based Adjuvant Chemotherapy

Ppar Signaling Pathway May Be an Important Predictor of Breast Cancer Response to Neoadjuvant Chemotherapy

An ERCC4 Regulatory Variant Predicts Grade-3 Or-4 Toxicities in Patients with Advanced Non-Small Cell Lung Cancer Treated by Platinum-Based Therapy

RB1 Polymorphism Contributes to the Efficacy of Platinum-Taxanes in Advanced Squamous Cell Lung Cancer.

Association of LncRNA MEG3 Polymorphisms with Efficacy of Neoadjuvant Chemotherapy in Breast Cancer

[Correlation between single nucleotide polymorphisms of rs4778137 located in OCA2 gene and clinical response of breast cancer patients receiving neoadjuvant chemotherapy]